NCT01625026View on ClinicalTrials.gov

Obeticholic Acid in Bariatric and Gallstone Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
ObesityGallstones
Interventions
DRUG

Obeticholic acid

Obeticholic acid 25 mg/day in three weeks

DRUG

Placebo

Placebo to obeticholic acid

Trial Locations (1)

411 31

Hanns-Ulrich Marschall, Gothenburg

All Listed Sponsors
collaborator

Medical University of Vienna

OTHER

lead

Sahlgrenska University Hospital

OTHER

NCT01625026 - Obeticholic Acid in Bariatric and Gallstone Disease | Biotech Hunter | Biotech Hunter